De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

NGM Biopharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO NGM Biopharmaceuticals' is David Woodhouse, benoemd in Sep2018, heeft een ambtstermijn van 5.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.93M, bestaande uit 10.3% salaris en 89.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde $ 179.29K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 5.6 jaar.

Belangrijke informatie

David Woodhouse

Algemeen directeur

US$5.9m

Totale compensatie

Percentage CEO-salaris	10.3%
Dienstverband CEO	5.6yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

Recent updates

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

Dec 19

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Oct 05

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Aug 09

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Jun 27

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Apr 17

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

Dec 20

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Oct 17

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

Jun 30

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Jun 21

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jun 15

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

May 09

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

Apr 26

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Feb 21

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Nov 08

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

Jul 09

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 06

Analyse CEO-vergoeding

Hoe is David Woodhouse's beloning veranderd ten opzichte van NGM Biopharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	n/a	n/a	-US$142m
Sep 30 2023	n/a	n/a	-US$151m
Jun 30 2023	n/a	n/a	-US$170m
Mar 31 2023	n/a	n/a	-US$178m
Dec 31 2022	US$6m	US$610k	-US$163m
Sep 30 2022	n/a	n/a	-US$153m
Jun 30 2022	n/a	n/a	-US$135m
Mar 31 2022	n/a	n/a	-US$125m
Dec 31 2021	US$10m	US$580k	-US$120m
Sep 30 2021	n/a	n/a	-US$121m
Jun 30 2021	n/a	n/a	-US$122m
Mar 31 2021	n/a	n/a	-US$111m
Dec 31 2020	US$5m	US$525k	-US$102m
Sep 30 2020	n/a	n/a	-US$90m
Jun 30 2020	n/a	n/a	-US$72m
Mar 31 2020	n/a	n/a	-US$54m
Dec 31 2019	US$2m	US$490k	-US$43m
Sep 30 2019	n/a	n/a	-US$13m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$5m
Dec 31 2018	US$4m	US$413k	-US$493k

Compensatie versus markt: De totale vergoeding ($USD 5.93M ) David } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 667.78K ).

Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

David Woodhouse (52 yo)

5.6yrs

Tenure

US$5,933,500

Compensatie

Dr. David J. Woodhouse, Ph D., has been an Independent Director of Surrozen, Inc. since September 2020. Dr. Woodhouse joined the Surrozen, Inc. in September 2020.Dr. Woodhouse served as Acting Chief Finan...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
William Rieflin	Executive Chairman of the Board of Directors	13.5yrs	US$1.10m	3.32% $ 4.3m
David Woodhouse	CEO & Director	5.6yrs	US$5.93m	0.14% $ 179.3k
Valerie Pierce	Senior VP	4.5yrs	US$2.10m	0.022% $ 28.7k
Hsiao Lieu	Chief Medical Officer & Executive VP	5.1yrs	US$2.73m	0.017% $ 22.3k
Jean Frederic Viret	Chief Financial Officer	1.3yrs	geen gegevens	geen gegevens
Irene Perlich	VP, Corporate Controller & Principal Accounting Officer	less than a year	geen gegevens	0.011% $ 13.8k
Daniel Kaplan	Chief Scientific Officer	1.3yrs	geen gegevens	geen gegevens
Mahi Saraf	Director of People & Culture	less than a year	geen gegevens	geen gegevens
Diana Bockus	Head of Business Development	1.8yrs	geen gegevens	geen gegevens
Arthur Hsu	Senior Director & Head of Biology	1.3yrs	geen gegevens	geen gegevens
Kara Calhoun	Senior Vice President of CMC & Process Development	less than a year	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NGM wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
William Rieflin	Executive Chairman of the Board of Directors	13.5yrs	US$1.10m	3.32% $ 4.3m
David Woodhouse	CEO & Director	5.6yrs	US$5.93m	0.14% $ 179.3k
Grant Heidrich	Special Advisor	no data	geen gegevens	geen gegevens
Arthur Levinson	Special Advisor	no data	geen gegevens	geen gegevens
David Goeddel	Lead Independent Director	5.6yrs	US$270.23k	19.87% $ 25.5m
Michael Brown	Chairman of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Joseph Goldstein	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Roger Perlmutter	Independent Director	2.8yrs	US$250.00k	0% $ 0
Shelly Guyer	Independent Director	4.3yrs	US$273.09k	0% $ 0
Robert Schreiber	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Suzanne Hooper	Independent Director	5.7yrs	US$265.00k	0.0084% $ 10.8k
Michael Fischbach	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

5.6yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NGM wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

NGM Biopharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Ngm Biopharmaceuticals, Inc. Appoints Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

NGM Biopharmaceuticals, Inc. Announces Appointment of Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

Insufficient new directors

Founder exercised options and sold US$316k worth of stock

Lead Independent Director recently bought US$462k worth of stock

NGM Biopharmaceuticals, Inc. Announces Executive Changes

Recent updates

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals, Inc. announced that it has received $122 million in funding from The Column Group, LLC and other investors

NGM Biopharmaceuticals Files Form 15

The Column Group, LLC completed the acquisition of 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders.

The Column Group, LLC entered into a definitive Agreement to acquire 74% stake in NGM Biopharmaceuticals, Inc. (NasdaqGS:NGM) from other group of shareholders for approximately $130 million.

NGM Biopharmaceuticals to Become Privately Held Company and its Shares to be No Longer Listed on Nasdaq as Result of Closing of the Tender Offer

NGM Bio Announces New Clinical Data from Ongoing Trial of Ngm707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and Ngm120 to Focus on Rare Conditions with Significant Unmet Need

What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You

NGM Biopharmaceuticals Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NGM Biopharmaceuticals, Inc. Presents Positive Phase 2b Results from the Alpha 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target decreased by 19% to US$4.83

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate

Ngm Biopharmaceuticals, Inc. Appoints Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

NGM Biopharmaceuticals, Inc. Announces Appointment of Irene Perlich as Principal Accounting Officer, Effective September 15, 2023

Consensus revenue estimates fall by 26%

Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Insufficient new directors

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky

Consensus revenue estimates decrease by 47%, EPS upgraded

First quarter 2023 earnings: EPS and revenues miss analyst expectations

NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't

Consensus EPS estimates fall by 23%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Founder exercised options and sold US$316k worth of stock

We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully

NGM Biopharmaceuticals, Inc. Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting

Price target increased to US$6.20

NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ngm Biopharmaceuticals, Inc. Announces Presentation of Post-Hoc Analyses from Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration At the Retina Society Annual Scientific Meeting

Lead Independent Director recently bought US$462k worth of stock

Ngm Biopharmaceuticals, Inc. (Ngm Bio) Announces Topline Efficacy and Safety Results from Its Randomized, Double-Masked, Sham-Controlled Catalina Phase 2 Trial of Ngm621 in Patients with Geographic Atrophy (Ga) Secondary to Age-Related Macular Degeneration

Price target decreased to US$28.75

NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails

Consensus revenue estimates fall by 11%

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.48 loss in 2Q 2021)

Price target decreased to US$32.50

NGM Biopharmaceuticals, Inc. Announces Executive Changes

NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President

NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

NGM Biopharmaceuticals, Inc. Announces Initiation of Phase 1/1B Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

Consensus forecasts updated

Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad

NGM Biopharmaceuticals, Inc. to Present Late-Breaking Preclinical Research at 2022 AACR Annual Meeting Supporting Development of its Myeloid Reprogramming Portfolio

NGM Biopharmaceuticals, Inc., Annual General Meeting, May 18, 2022

NGM Biopharmaceuticals, Inc. Announces It Has Dosed the First Patient in A Phase 1/1B Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth

CEO & Director exercised options to buy US$313k worth of stock.

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.43 loss in 3Q 2020)

High number of new directors

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Price target increased to US$31.50

NGM Biopharmaceuticals, Inc. Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research

Chief Medical Officer & Senior VP recently sold US$52k worth of stock

Founder notifies of intention to sell stock

Second quarter 2021 earnings released: US$0.48 loss per share (vs US$0.38 loss in 2Q 2020)

Consensus EPS estimates fall to -US$1.70